Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
14.99
+0.07 (+0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acadia Pharmaceutica
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 02, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
April 25, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 20, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher
April 17, 2023
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else?
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
April 14, 2023
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
March 20, 2023
Via
Benzinga
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
March 13, 2023
Via
Benzinga
1 Top Biotech Stock to Buy in March
March 07, 2023
This biotech could land a major regulatory approval this month.
Via
The Motley Fool
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
April 17, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Looking Into ACADIA Pharmaceuticals's Return On Capital Employed
March 02, 2023
Via
Benzinga
Analysts See Steady Growth For Acadia Pharma's Nuplazid
February 28, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
February 28, 2023
Via
Benzinga
Earnings Preview For ACADIA Pharmaceuticals
February 24, 2023
Via
Benzinga
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug
March 14, 2023
The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older.
Via
Benzinga
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
March 14, 2023
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...
Via
Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...
Via
Benzinga
3 Nasdaq Stocks on Watch This Week
March 12, 2023
These three Nasdaq stocks are poised to make big moves in the coming week.
Via
The Motley Fool
Analyst Expectations for ACADIA Pharmaceuticals's Future
January 31, 2023
Via
Benzinga
Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
December 21, 2022
Via
Benzinga
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
March 10, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
March 03, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
February 27, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
February 14, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Earnings Scheduled For February 27, 2023
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
January 09, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
January 03, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
December 21, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.